Scott Galasinski

Scott Galasinski is a highly experienced professional in the biotechnology and pharmaceutical industries, currently serving as a Scientific and Medical Advisory Board Member for The Schinzel-Giedion Syndrome Foundation and a Scientific Advisory Board Member for iDefine. As the Head of Business Development and Strategy at Molecular Axiom, Scott is focused on developing precision-medicine strategies for pancreatic ductal adenocarcinoma. Scott's past roles include VP and Global Head of Business Development at AstraZeneca, Vice President at Novartis Gene Therapies, and Executive Director at Ultragenyx Pharmaceutical Inc., where significant contributions were made toward advancing treatments for rare diseases. Educational qualifications include a Ph.D. in Molecular, Cellular, and Developmental Biology from the University of Colorado Boulder, alongside postdoctoral research in Epigenetics from Penn State University.